52Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Singapore
Neuroscience Intelligence
Singapore neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #34 of 50 · Data maturity A · Research score 31.7 · Data confidence 100.0 / 100 · Snapshot 2026-10-29 06:18 UTC.
13Recruiting trials
56Publications
47Institutions
Executive interpretation
Singapore ranks #34 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. Clinical metrics and NCT evidence use only records classified as in_scope or related; out_of_scope records remain preserved outside these analytical counts. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Merck Sharp & Dohme LLC54 recruiting
National University Hospital, Singapore41 recruiting
National University of Singapore30 recruiting
National Neuroscience Institute32 recruiting
National Healthcare Group, Singapore30 recruiting
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.30 recruiting
Institute of Mental Health, Singapore30 recruiting
Eisai Inc.22 recruiting
Hoffmann-La Roche21 recruiting
Singapore General Hospital20 recruiting
Disease activity
Alzheimers12trials
Stroke8trials
Autism6trials
Parkinsons5trials
Dementia Other3trials
Other Neurology3trials
Depression3trials
Epilepsy3trials
Neuro Oncology2trials
Other Psychiatry2trials
Research institutions
A*STAR-NUS Clinical Imaging Research CentreOpenAlexlinked institution
Ngee Ann PolytechnicOpenAlexlinked institution
Cancer Science Institute of SingaporeOpenAlexlinked institution
National University Heart Centre SingaporeOpenAlexlinked institution
KK Women's and Children's HospitalOpenAlexlinked institution
Ng Teng Fong General HospitalOpenAlexlinked institution
Singapore Management UniversityOpenAlexlinked institution
Duke-NUS Medical SchoolOpenAlexlinked institution
Singapore General HospitalOpenAlexlinked institution
Singapore Bioimaging ConsortiumOpenAlexlinked institution
Clinical evidence trail
NCT07210528Safety Of Nrtis for Alzheimer's Therapeutic Advancement in Singapore StudyACTIVE_NOT_RECRUITING
NCT07033494A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)RECRUITING
NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RECRUITING
NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RECRUITING
NCT06894225Proof-of-Concept Study of ACT001 in Adult Patients With Recurrent Glioblastoma Harbouring STAT3-High SignatureRECRUITING
NCT06563895Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantRECRUITING
NCT05503264A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) EncephalitisACTIVE_NOT_RECRUITING
NCT05239728A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)ACTIVE_NOT_RECRUITING
NCT04468659AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate AmyloidACTIVE_NOT_RECRUITING
NCT03887455A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's DiseaseACTIVE_NOT_RECRUITING
Research evidence trail
PUBMEDGlycine transporter 1 inhibitor, bitopertin, changes excitatory and inhibitory network connectivity in mouse medial prefrontal cortex.2026-12-15
PUBMEDA meta-analysis of functional brain activity during valence processing in internet gaming disorder and gambling disorder.2026-12-01
PUBMEDRetrosigmoid craniotomy surgical guide: The way forward for precise exposure of the transverse-sigmoid sinuses.2026-11-01
PUBMEDPsychological adversities and epigenetic ageing in midlife and older age: A systematic review and meta-analysis.2026-11-01
PUBMEDα-Synuclein Seeds Amplification Assays for Parkinson's Disease and Related Synucleinopathies.2026-11-01
PUBMEDDepression in the prodromal phase of Parkinson's disease: Clinical manifestations, biomarker evidence, and predictive implications.2026-10-21
PUBMEDStatin Exposure and Survival Outcomes in Amyotrophic Lateral Sclerosis in an Asian Cohort.2026-10-12
PUBMEDAssociation of stenosis and arterial remodeling with cerebral hemodynamics and cognition.2026-10-08
PUBMEDExercise and multidomain interventions for vascular cognitive impairment: A narrative review.2026-10-01
PUBMEDExcitation-inhibition imbalance links amyloid pathophysiology to cognition in non-demented individuals.2026-10-01
PUBMEDCHCHD2 and CHCHD10 promoted autophagic clearance of protein aggregates via GABARAPs.2026-10-01
PUBMEDSleep fragmentation and heightened inflammation: A latent profile subtype predicting nine-year major depressive disorder severity in the MIDUS study.2026-10-01
World Bank context
Macro indicators are shown only where a timestamped World Bank source row exists. Latest collection in this report: 2026-10-24 04:18 UTC. They are context, not NeuroRisk predictions.
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.